Western immunoblotting and enzymatic activity analysis of cathepsin D in human breast cancer cell lines of different invasive potential. Regulation by 17beta-estradiol, tamoxifen and ICI 182,780.
We used enzymatic activity and immunochemical quantifications to analyse the expression and secretion of cathepsin D by human breast cancer cell lines of different invasive potentials (MCF-7/6, MCF-7/AZ, MDA-MB-231). This study does not directly prove that cathepsin D or procathepsin D is involved in human breast cancer cell invasion and metastasis but it shows that the proportion of procathepsin D (activity and antigen) secreted by the human breast cancer cell lines tested correlates with their invasive potential. In the estrogen receptor-positive MCF-7 subclones, this proportion is increased by estradiol only in the invasive MCF-7/6 variant. The cell content in procathepsin D is increased by estrogens to a greater extent in MCF-7/6 cells as compared to non-invasive MCF-7/AZ cells. Tamoxifen appears to be an estrogen agonist concerning cathepsin D regulation, whereas ICI 182,780 is a true antagonist. Our results suggest that synthesis and secretion of cathepsin D are regulated at two distinct levels and differentially affected by estrogens. Synthesis only seems to be affected in non-invasive MCF-7/AZ cells, whereas in invasive MCF-7/6 cells, both synthesis and the efficiency of secretion are increased by estrogens. Our results also confirm that the key site of regulation leading to lysosomal enzyme oversecretion is the Golgi apparatus insulin-like growth factor-II/mannose 6-phosphate receptor.
Couissi
D
D
Laboratory of Cell Biology, Université Catholique de Louvain, Louvain-la-Neuve, Belgium.
Dubois
V
V
Remacle
C
C
Schonne
E
E
Trouet
A
A
D000143:Acids; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents / Q000494:pharmacology; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D002402:Cathepsin D / Q000187:drug effects / Q000378:metabolism*; D016895:Culture Media, Serum-Free; D004789:Enzyme Activation; D004792:Enzyme Precursors / Q000187:drug effects / Q000378:metabolism; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology*; D004965:Estrogen Antagonists / Q000494:pharmacology*; D000077267:Fulvestrant; D006801:Humans; D015151:Immunoblotting; D009361:Neoplasm Invasiveness; D013629:Tamoxifen / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000143:Acids; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D016895:Culture Media, Serum-Free; D004792:Enzyme Precursors; D004965:Estrogen Antagonists; D013629:Tamoxifen; D000077267:Fulvestrant; D004958:Estradiol; C058345:procathepsin D; D002402:Cathepsin D